Revelstone provides responsive, objective, thorough, agile, efficient, and effective solutions during your pivotal and transformational periods. 

As your professional partner, we support you from start to finish, with integrity, objectivity, creativity, and enthusiasm. Understanding and meeting your challenges knowledgeably through our experience from drug discovery to life-cycle management in industrial, academic, to hybrid organizations is pivotal. 

Success is built upon our excellent track record in orphan diseases, pediatric CNS disorders, epilepsy, complex botanical drug development, exclusivity, translational science, controlled drug development, DEA interaction, and patient group engagement. Revelstone's regulatory experience and familiarity includes global agencies demonstrated by EMA rapporteur negotiations, and importantly, FDA Advisory Committees that received unanimous favorable votes.

Revelstone works proactively in successful negotiation with US and European regulatory agencies, navigation of post-marketing requirements, regulatory exclusivity, Orange Book and legal patents (including novel approaches to controlled drug, composition, and nutraceutical strategies). Our founders and partners are the named inventors of dozens of patents, many of which rely upon new chemical entities, novel exclusivity strategies, complex botanicals, and controlled drugs; we are here to enhance and protect your portfolio.

As you would expect, Revelstone offers the expected experience and knowledge that accompanies all regulatory filings from first in human studies to Phase IV and globalization. Our disease expertise is broad and includes clinical, regulatory, and scientific specialists in pathophysiology and treatment of a range of orphan diseases, orphan drugs, refractory childhood epilepsies associated diseases, multiple sclerosis, essential tremor, nanobody delivery, dementia symptoms, and Parkinson’s Disease.

Revelstone Consulting

Org chart

Teams

Offices